Healthcare provider profile · identity verified

Debra L Dollar, MD

Internal Medicine · AUSTIN, TX · NPI 1275549545

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	335	86
Atorvastatin Calcium	Atorvastatin Calcium	312	85
Rosuvastatin Calcium	Rosuvastatin Calcium	250	60
Amlodipine Besylate	Amlodipine Besylate	197	58
Losartan Potassium	Losartan Potassium	194	42
Metformin Hcl Er	Metformin Hcl	173	49
Ozempic	Semaglutide	169	22
Escitalopram Oxalate	Escitalopram Oxalate	166	45
Lisinopril	Lisinopril	144	37
Gabapentin	Gabapentin	136	33
Meloxicam	Meloxicam	132	40
Synthroid	Levothyroxine Sodium	132	28
Metoprolol Succinate	Metoprolol Succinate	130	36
Hydrochlorothiazide	Hydrochlorothiazide	124	30
Trazodone Hcl	Trazodone Hcl	117	25
Jardiance	Empagliflozin	116	21
Omeprazole	Omeprazole	110	33
Sertraline Hcl	Sertraline Hcl	100	21
Zolpidem Tartrate	Zolpidem Tartrate	97	21
Estradiol	Estradiol	93	34
Montelukast Sodium	Montelukast Sodium	84	24
Pravastatin Sodium	Pravastatin Sodium	78	20
Fluticasone Propionate	Fluticasone Propionate	77	30
Pantoprazole Sodium	Pantoprazole Sodium	72	22
Metformin Hcl	Metformin Hcl	70	19
Duloxetine Hcl	Duloxetine Hcl	66	12
Fluoxetine Hcl	Fluoxetine Hcl	66	16
Simvastatin	Simvastatin	63	20
Potassium Chloride	Potassium Chloride	58	21
Bupropion Xl	Bupropion Hcl	56	13
Alprazolam	Alprazolam	55	18
Metoprolol Tartrate	Metoprolol Tartrate	55	13
Mounjaro	Tirzepatide	53	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	50	21
Olmesartan Medoxomil	Olmesartan Medoxomil	49	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	47	12
Atenolol	Atenolol	44	12
Glipizide Er	Glipizide	43	13
Furosemide	Furosemide	39	12
Risedronate Sodium	Risedronate Sodium	39	suppressed
Trulicity	Dulaglutide	38	suppressed
Celecoxib	Celecoxib	36	12
Tamsulosin Hcl	Tamsulosin Hcl	36	11
Tramadol Hcl	Tramadol Hcl	36	suppressed
Valacyclovir	Valacyclovir Hcl	36	21
Citalopram Hbr	Citalopram Hydrobromide	34	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	32	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	32	suppressed
Azelastine Hcl	Azelastine Hcl	31	13
Januvia	Sitagliptin Phosphate	30	suppressed
Raloxifene Hcl	Raloxifene Hcl	30	suppressed
Alendronate Sodium	Alendronate Sodium	29	suppressed
Famotidine	Famotidine	29	suppressed
Benazepril Hcl	Benazepril Hcl	28	suppressed
Diclofenac Sodium	Diclofenac Sodium	28	suppressed
Ezetimibe	Ezetimibe	28	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	28	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	27	suppressed
Spironolactone	Spironolactone	26	suppressed
Clonidine Hcl	Clonidine Hcl	25	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	25	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	24	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	24	suppressed
Dotti	Estradiol	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Allopurinol	Allopurinol	22	suppressed
Nebivolol Hcl	Nebivolol Hcl	22	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	21	suppressed
Np Thyroid	Thyroid,pork	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	20	suppressed
Carvedilol	Carvedilol	19	suppressed
Clopidogrel	Clopidogrel Bisulfate	19	suppressed
Lovastatin	Lovastatin	19	suppressed
Solifenacin Succinate	Solifenacin Succinate	19	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	18	suppressed
Valsartan	Valsartan	18	suppressed
Diazepam	Diazepam	17	suppressed
Eliquis	Apixaban	17	suppressed
Ketoconazole	Ketoconazole	17	12
Paroxetine Hcl	Paroxetine Hcl	17	suppressed
Irbesartan	Irbesartan	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	15	suppressed
Dexlansoprazole Dr	Dexlansoprazole	15	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	14	suppressed
Glipizide	Glipizide	14	suppressed
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	14	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Propranolol Hcl Er	Propranolol Hcl	13	suppressed
Ramipril	Ramipril	13	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Carisoprodol	Carisoprodol	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Fenofibrate	Fenofibrate	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	11	suppressed
Mometasone Furoate	Mometasone Furoate	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	11	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error